• Home
  • Cost per remission and cost per response with infliximab, adalimumab, and golimumab for the treatment of moderately-to-severely active ulcerative colitis.

Cost per remission and cost per response with infliximab, adalimumab, and golimumab for the treatment of moderately-to-severely active ulcerative colitis.

Author List
Toor K, Druyts E, Jansen JP, Thorlund K
Publication
Journal of medical economics
Publication ID (Profile URL)
https://researcherprofiles.org/profile/102292355
Publication Year
2015
PubMed ID
25629655
Publication Title
Toor K, Druyts E, Jansen JP, Thorlund K. Cost per remission and cost per response with infliximab, adalimumab, and golimumab for the treatment of moderately-to-severely active ulcerative colitis. J Med Econ. 2015 Jun; 18(6):437-46.